What digital biomarkers measure
Digital biomarkers for neurodegenerative disease tracking are objective, quantifiable measures collected through connected devices and software. They can capture changes in movement, speech, sleep, cognition, medication response, and daily function—often between clinic visits. They do not replace a neurological examination, imaging, genetic testing, or clinician judgement. Their value is to add frequent, real-world evidence to those established methods.
For a person with Parkinson’s disease, a phone or wearable may record tremor, gait speed, step regularity, or “on-off” fluctuations. For Alzheimer’s disease and related dementias, an app may measure reaction time, memory performance, speech pauses, or changes in routine. In multiple sclerosis, mobility and balance data can complement relapse and disability assessments. These signals are most useful when they are linked to a defined clinical question rather than collected simply because a device makes measurement possible.
Data sources and practical signals
A robust programme usually combines several low-burden sources:
- Smartphones: tapping tests, voice samples, walking tasks, location patterns, and app-based cognitive assessments.
- Wearables: accelerometer and gyroscope data, tremor, gait, heart rate, sleep, activity levels, and sometimes oxygen saturation.
- Home sensors: room movement, transfers from a chair, sleep environment, and medication routines, where consent and installation are appropriate.
- Telehealth workflows: structured questionnaires, video-based movement reviews, and patient-reported outcomes.
- Clinical records: diagnosis, medication timing, adverse effects, examination scores, and imaging or laboratory results used for context.
The strongest indicators are not necessarily the most complex. A repeatable five-minute walking test may be more useful than an opaque score generated from dozens of passive variables. Teams should document the device, software version, sampling rate, missing-data rules, test instructions, and intended interpretation for every measure.
How tracking works in practice
A clinically credible workflow has five stages:
1. Define the use case. Decide whether the tool is intended for screening, progression tracking, treatment-response measurement, trial recruitment, or safety monitoring. Screening and diagnosis require a higher evidence threshold than exploratory research.
2. Establish a baseline. Collect data during a stable period and record medication timing, sleep disruption, illness, travel, and device changes. A baseline reduces the risk of mistaking a person’s normal variability for deterioration.
3. Collect consistently. Use clear instructions, reminders, calibration checks, and offline options. Passive data should not be treated as complete when the phone was left at home or the wearable battery was flat.
4. Analyse change, not isolated readings. Look for sustained trends and clinically meaningful thresholds. A single poor walking score may reflect pain, anxiety, or a crowded environment rather than disease progression.
5. Create an action pathway. Every alert needs an owner, response time, escalation rule, and documentation process. If nobody reviews the signal, continuous monitoring becomes expensive data storage.
This approach also applies to wider AI for early disease detection in India, where model outputs must be connected to confirmatory testing and care pathways rather than presented as diagnoses.
Disease-specific applications
Parkinson’s disease: Movement data can help quantify tremor, bradykinesia, dyskinesia, gait freezing, turning, and medication fluctuations. A useful system records medication schedules and asks about contextual factors, because the same movement score can mean different things before and after a dose.
Alzheimer’s disease and mild cognitive impairment: Digital cognitive tasks, speech analysis, navigation behaviour, and changes in daily routines may reveal trends that short clinic assessments miss. These tools should account for language, education, hearing, literacy, device familiarity, and caregiver involvement. Performance in an English-only app should not be assumed to generalise across India’s linguistic diversity.
Multiple sclerosis: Smartphone mobility tests, balance measures, fatigue diaries, and activity patterns can support longitudinal monitoring. Because fatigue, heat, sleep, and mood can influence performance, interpretation should combine sensor data with patient-reported context.
Huntington’s disease and related conditions: Fine motor control, speech, involuntary movement, and cognition are potential targets. Research systems need careful participant support because symptoms and functional needs can change over time.
Evidence, validation, and AI governance
A digital measure should demonstrate more than technical accuracy. Teams need to establish analytical validity—whether the device measures the intended signal reliably—along with clinical validity, meaning whether the signal relates to a recognised disease state or outcome. Clinical utility asks the harder question: does using the measure improve decisions, outcomes, trial efficiency, or quality of life?
Validation should include diverse ages, skin tones where optical sensors are used, languages, rural and urban settings, different phones, varied internet access, and people with disabilities. Compare the digital signal with accepted clinical scales and patient-relevant outcomes. Report attrition, missing data, false alerts, subgroup performance, and how the model behaves after software updates.
Machine learning can detect patterns that are difficult to programme manually, but a high-performing model is not automatically safe. Freeze model versions for trials, monitor drift after deployment, keep an audit trail, and give clinicians a way to review the underlying trend. Teams evaluating AI systems can borrow disciplined practices from best tools for LLM evaluation and experiment tracking, especially version control, reproducible tests, and performance monitoring.
Privacy, consent, and India-specific deployment
Neurodegenerative disease data can reveal health status, routines, location, household activity, and caregiver relationships. Consent should explain what is collected, how often, why it is needed, who can access it, how long it will be retained, and whether it will be used for research or commercial development. Give participants a practical way to pause collection, withdraw, correct records, and request support.
Deployments in India should align their data practices with the Digital Personal Data Protection Act, 2023, applicable rules, institutional ethics requirements, and relevant health-data security controls. Use data minimisation, encryption in transit and at rest, role-based access, pseudonymisation, breach procedures, and clear vendor contracts. Do not assume that a consumer wellness device is suitable for clinical use merely because it has a health-related feature.
Accessibility is equally important. Offer local-language instructions, low-cost or loaner devices, assisted onboarding, telephone alternatives, and workflows that function with intermittent connectivity. A system that excludes older adults, people without smartphones, or families sharing one device may produce biased evidence and worse service delivery.
A builder’s implementation checklist
Before launching a pilot, specify:
- The clinical decision or research endpoint the biomarker supports.
- The minimum device and connectivity requirements.
- Baseline duration, assessment frequency, and acceptable missingness.
- Device calibration, replacement, support, and battery procedures.
- Data dictionary, retention schedule, access permissions, and consent language.
- Alert thresholds, human review, escalation, and emergency disclaimers.
- Validation plan, subgroup analysis, model monitoring, and independent review.
- Cost per participant and a sustainability plan beyond the grant or pilot.
Start with one measurable use case and a small, representative cohort. Involve neurologists, rehabilitation specialists, patients, caregivers, data scientists, security teams, and ethics reviewers from the beginning. A simple, trusted workflow that produces actionable evidence is more valuable than a feature-heavy app with poor adherence.
What comes next
By 2026, the field is moving from novelty claims toward fit-for-purpose evidence. Better sensors, edge processing, multimodal models, and interoperable clinical systems will improve measurement, but adoption will depend on validation, affordability, clinician workflow, and patient trust. Digital biomarkers are best treated as a layer in a broader care system—not as an automated diagnosis engine.
For funders and builders, the most credible proposals will define the unmet clinical need, quantify the burden on patients and staff, disclose model limitations, and show how the tool works in India’s real conditions. The goal is not to collect more data. It is to detect meaningful change earlier, reduce unnecessary clinic burden, support better treatment decisions, and give patients a clearer view of their own disease journey.